New Slow-Release olanzapine shots aim to simplify schizophrenia treatment
NCT ID NCT06319170
First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 20 times
Summary
This completed Phase 1 trial tested three different slow-release versions of the schizophrenia drug olanzapine in 106 adults with schizophrenia or schizoaffective disorder. The goal was to see how the body absorbs and processes each version compared to the standard immediate-release injection. Researchers also monitored safety and side effects over 28 days after a single shot.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Teva Investigational Site 15726
Marlton, New Jersey, 08053, United States
-
Teva Investigational Site 15727
Hollywood, Florida, 33024, United States
-
Teva Investigational Site 15728
Decatur, Georgia, 30030, United States
-
Teva Investigational Site 15729
Atlanta, Georgia, 30331, United States
-
Teva Investigational Site 15730
Los Alamitos, California, 90720, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
olanzapine (extended-release injection)
What this could lead to
If successful, this could lead to a longer-acting version of olanzapine that requires less frequent injections, making it easier for people with schizophrenia to stay on treatment.
What could go wrong
This is an early Phase 1 study focused on drug levels in the body, not on how well the drug works. The new formulations may not prove safer or more effective than the current version.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.